Results 41 to 50 of about 78,382 (206)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma [PDF]

Cancer Medicine, 2016
AbstractDespite major advances in the treatment of metastatic melanoma, treatment failure is still inevitable in most cases. Manipulation of key epigenetic regulators, including inhibition of Bromodomain and extra‐terminal domain (BET) family members impairs cell proliferation in vitro and tumor growth in vivo in different cancers, including melanoma ...
Paoluzzi, Luca, Hanniford, Douglas, Sokolova, Elena, Osman, Iman, Darvishian, Farbod, Wang, Jinhua, Bradner, James E., Hernando, Eva   +7 more
openaire   +2 more sources

Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas

Nature Communications, 2023
While targeted treatment against BRAF(V600E) improve survival for melanoma patients, many will see their cancer recur. Here we provide data indicating that epigenetic suppression of PGC1α defines an aggressive subset of chronic BRAF-inhibitor treated ...
Jiaxin Liang, Deyang Yu, Chi Luo, Christopher Bennett, Mark Jedrychowski, Steve P. Gygi, Hans R. Widlund, Pere Puigserver   +7 more
doaj   +1 more source

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

OncoImmunology, 2017
The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select
Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Diana Giannarelli, Vito Vanella, Marco Palla, Marcello Curvietto, Assunta Esposito, Giuseppe Palmieri, Nicola Mozzillo, Paolo Antonio Ascierto   +10 more
doaj   +1 more source

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas [PDF]

Frontiers in Oncology, 2018
Low-grade gliomas (LGG) are the most common central nervous system tumors in children. Prognosis depends on complete surgical resection. For patients not amenable of gross total resection (GTR) new approaches are needed. The BRAF mutation V600E is critical for the pathogenesis of pediatric gliomas and specific inhibitors of the mutated protein, such as
Francesca Del Bufalo, Giulia Ceglie, Antonella Cacchione, Iside Alessi, Giovanna Stefania Colafati, Andrea Carai, Francesca Diomedi-Camassei, Emmanuel De Billy, Emanuele Agolini, Angela Mastronuzzi, Franco Locatelli, Franco Locatelli   +11 more
openaire   +3 more sources

Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

BMC Cancer, 2018
Background More than 50% of metastatic melanoma patients have a specific mutation in the serine/threonine kinase BRAF. This results in constitutive activation of the RAS-RAF-MEK-ERK-MAP kinase pathway, which causes uncontrolled cell growth.
Jingjing Xiao, Michael E. Egger, Kelly M. McMasters, Hongying Hao   +3 more
doaj   +1 more source

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

Frontiers in Oncology, 2022
BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency.
Yang Yu, Min Yu, Yanying Li, Xiaojuan Zhou, Tian Tian, Yijia Du, Zegui Tu, Meijuan Huang   +7 more
doaj   +1 more source

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E., Berger, Adam C., Bollag, Gideon, Davies, Michael A., Goldberg, Allison F., Hartsough, Edward J., Knudsen, Karen E., Kugel, Curtis H., Purwin, Timothy J., Schiewer, Matthew J., Vido, Michael J.   +10 more
core   +1 more source

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]

, 2015
The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva, A Snyder, Adam Bloomfield, AM Broadbent, Andrew Furness, Anna Wilkins, C Nieder, C Nieder, D Mathieu, D Rades, E Weltman, FE Harrell Jr, GV Long, J Larkin, J Lorenzoni, J Raizer, James Larkin, JG Lorenzoni, K Margolin, Kevin Harrington, LE Gaspar, M Staudt, MA Hofmann, Nuria Porta, P Royston, PC Tumeh, PW Sperduto, PW Sperduto, R Dummer, R Fisher, R Partl, Richard W Corbett, SL Morris, Stephen Morris, T Serizawa, TK Eigentler, Zohra Ali   +36 more
core   +2 more sources

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer

Cancer Immunology, Immunotherapy
BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials.
Eunyoung Tak, Hye-In An, Amy Sinyoung Lee, Kyuyoung Han, Jiwan Choi, Hyung-don Kim, Yong Sang Hong, Sun Young Kim, Eun Kyung Choi, Jeong Eun Kim, Tae Won Kim   +10 more
doaj   +1 more source

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ

Neoplasia: An International Journal for Oncology Research, 2017
Treatment of BRAF mutant melanoma with kinase inhibitors has been associated with rapid tumor regression; however, this clinical benefit is short-lived, and most patients relapse.
Laura J. Vella, Andreas Behren, Bradley Coleman, David W. Greening, Andrew F. Hill, Jonathan Cebon   +5 more
doaj   +1 more source